Articles

RGX-314 is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions.

RGX-314 earns positive interim data in Phase 2 ALTITUDE trial for diabetic retinopathy

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of 

In a real-world setting, eyes with AMD with a relatively good initial best-corrected visual acuity and no fibrovascular pigment epithelial detachment sustained or improved BCVA after anti-VEGF therapy within 3 years of follow-up.

Timing is everything with early treatment of AMD

A previously uncharacterized area of the protein known as RPE65 spontaneously turns spiral-shaped when it encounters intracellular membranes, or thin structures that surround different parts of a cell.

NIH discovery uncovers essential step to recharging the retina

The Sailing study was a 12-month, 18-center, randomized, double-masked, double-sham, parallel-controlled, phase 3 trial that was conducted in China and included eyes with center-involved DME that were randomly assigned to undergo either laser photocoagulation followed by as-needed sham intravitreal injections or sham laser photocoagulation followed by as-needed 0.5 mg intravitreal injections of conbercept.

Sailing study and extension study: Superiority of conbercept over laser in DME

Genentech announced this week that faricimab-svoa (Vabysmo) achieved its primary endpoint of non-inferiority compared to aflibercept in RVO in the BALATON and COMINO clinical trials.

Faricimab-svoa improved vision in patients with retinal vein occlusion, according to topline Phase 3 results

In this retrospective, non-comparative clinical study, the investigators evaluated the preoperative, intraoperative, and postoperative data of the 225 study patients (295 eyes; mean patient age, 56.1 years) collected from several European centers.

Cataract surgery in RP patients yield marked improvements in BCVA

Videos

Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.

TENAYA, LUCERNE year 2 data reveals promising results for faricimab

In both patients and controls, investigators measured retinal nerve fiber layer thickness, foveal avascular zone area, and vessel density in the superficial capillary plexus, deep capillary plexus, and radial peripapillary capillary plexus.

COPD & the eye: Ocular microstructures affected by chronic disease

The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.

Apellis to submit 24-month Phase 3 pegcetacoplan data to FDA, delays PDUFA date

An end-of-week review of retina news and stories from October 29-November 3, 2022.

COPD & the eye: Ocular microstructures affected by chronic disease

Apellis to submit 24-month Phase 3 pegcetacoplan data to FDA, delays PDUFA date

This week in retina: October 29-November 3